Sunshine Biopharma, Inc. (SBFM)
After hours:
| Previous Close | 0.9854 |
| Open | 1.0000 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 1100 |
| Day's Range | 0.9790 - 1.0400 |
| 52 Week Range | 0.6200 - 9.8700 |
| Volume | |
| Avg. Volume | 362,090 |
| Market Cap | 23.263M |
| Beta (5Y Monthly) | -1.13 |
| PE Ratio (TTM) | 1.39 |
| EPS (TTM) | 0.7400 |
| Earnings Date | Aug 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Sunshine Biopharma Announces Share Repurchase Program
MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with
- News Direct
Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares
By Jad Malaeb, Benzinga
- GlobeNewswire
Sunshine Biopharma’s Annual Letter to Shareholders
MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company. Dear Fellow Sunshine Biopharma Shareholders, On behalf of Sunshine’s Board of Directors, our senior management team, and employees, we are delighted to have you as our shareholder
